MedWatch

Health economist warns about eternal patent-threat

If government requirements concerning the production of biosimilars become too stringent, patent expirations will have no effect. A health economist now voices his concern that it will have a huge impact on the development of new drugs and our overall economy.

Foto: DSI/PR

It could be extremely costly and inhibiting to the development of new medicine, if the regulatory requirements for copies of biological medicine, also known as biosimilars, become too strict. The warning comes from health economist Jesper Nørregaard, following a recent seminar on biosimilars held by pharmaceutical company Roche.

“The worst case scenario is that if no biosimilars hit the market, this business model won’t work from the point of view of the authorities. Because the original product will see a continued increase in turnover and profit, and will never experience the “dip” that forces the company to invent something new,” says Jesper Nørregaard who is head of projects in DSI (Danish Health Institute).

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier